在肥胖的雄性小鼠中,eplerenone 改善了功能和心脏性能
Ayman K Banah1,2, Bingxue Qi1,3, Ryan Koh1
1Division of Diabetes, Endocrinology, and Reproductive Biology, School of Medicine, University of Dundee, Dundee, Scotland, UK.
概括
在肥胖小鼠中,eplerenone治疗通过减少脂肪质量和改善心脏和功能障碍,改善了心脏和功能. 这项研究揭示了矿物质皮质体受体与氨酸-CD44/RHAMM通路之间的新联系.
科学领域:
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 肥胖相关的心脏脏功能障碍与雷宁-安吉奥素-阿尔多斯素系统 (RAAS) 的激活有关.
- 在与肥胖有关的心脏代谢并发症中,RAAS抗的精确分子机制和临床实用性需要进一步阐明.
研究的目的:
- 研究选择性矿物质皮质类受体对抗剂eplerenone对肥胖患者心脏和功能的影响.
- 在肥胖的背景下探索eplerenone作用的潜在分子机制.
主要方法:
- 雄性C57BL/6小鼠在12周内被食高脂肪饮食 (HFD).
- 在HFD治疗期间,小鼠接受了30天的载体或eplerenone治疗.
- 通过压力-体积 (PV) 循环分析评估心脏功能,通过形态学和血清肌素评估功能.
主要成果:
- HFD诱导心脏和功能障碍,其特征是血压升高,球膜缩和管管损伤.
- 埃普莱伦治疗导致体重减轻 (主要是脂肪质量),并显著改善心脏表现和功能.
- 分子分析显示,eplerenone调节了心脏和脏中的hyaluronan-CD44/RHAMM通路,TGF-β,IL-6和Akt/JNK信号传递.
结论:
- 在肥胖的雄性小鼠中,eplerenone有效地改善了功能和心脏表现.
- 确定了矿物质皮质体受体活性与氨酸-CD44/RHAMM通路之间的新相关性.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
01:22Heart Failure Drugs: Diuretics
763
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763
01:30Heart Failure V: Medical Management
195
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
01:21Drug Dosing: Obese Patients
189
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
189
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
149
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
149
01:22Heart Failure Drugs: β-Blockers
724
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
724